When was PanOptica founded?

PanOptica was founded in 2009 and raised its 1st funding round 2 years after it was founded.

Where is PanOptica located?

PanOptica is headquartered in Bernardsville, United States. It is registered at Mount Arlington, New Jersey.

How many employees does PanOptica have?

As of Jul 31, 2026, the latest employee count at PanOptica is 4.

Is PanOptica a funded company?

PanOptica is a funded company, having raised a total of $86M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 04, 2011.

When was the latest funding round of PanOptica?

PanOptica's latest funding was a $***** Series B round on Apr 09, 2019, with participation from 3 investors. Its primary sector is Ophthalmology. In United States, the Ophthalmology sector has seen $1.46B in funding in 2026 to date.

Where does PanOptica rank among its competitors?

PanOptica ranks 863rd amongst 2671 active competitors, of which 901 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of PanOptica?

PanOptica's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

PanOptica - 2026 Company Profile, Funding & Competitors

PanOptica is a series B company based in Bernardsville (United States), founded in 2009. It operates as a Developer of small molecule therapeutics for ophthalmic disorders. PanOptica has raised $86M in funding from investors like Third Rock Ventures, SV Health Investors and Novo Holdings. The company has 2671 active competitors, including 901 funded and 682 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of small molecule therapeutics for ophthalmic disorders. The lead candidate PAN-90806 is a small molecule inhibitor of the VEGF protein for age-related macular degeneration and other neovascular eye diseases.

Website: www.panopticapharma.com/
Registered Address: Mount Arlington, New Jersey

Key Metrics

Founded Year

2009

Location

Bernardsville, United States

Stage

Series B

Total Funding

$86M in 3 rounds

Latest Funding Round

Series B, Apr 09, 2019, $*****

Investors

Third Rock Ventures & 3 more

Ranked

863^rd among 2671 active competitors

Employee Count

4 as on Jul 31, 2026

Similar Companies

Viridian Therapeutics & 300 more

View PanOptica's full profile

PanOptica is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Panoptica, Inc. CIN: 264346614 , United States, Active	Feb 26, 2009	-	5 (As on Dec 31, 2019)	-

PanOptica has raised a total funding of $86M over 3 rounds. Its first funding round was on Jan 04, 2011. Its latest funding round was a Series B round on Apr 09, 2019 for $*****. 3 investors participated in its latest round. PanOptica has 4 institutional investors.

Here is the list of recent funding rounds of PanOptica:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 09, 2019	9507621	Series B	9147745	3668795	9038241	8713633
Oct 06, 2017	7574156	Series B	2539169	7775425	4221789	Third Rock Ventures & 1 more
Jan 04, 2011	8931548	Series A	8328952	7481611	Third Rock Ventures & 1 more	4002450

Access funding benchmarks and valuations. Sign up today!

View details of PanOptica's funding rounds and investors

PanOptica's employee count trend

PanOptica has 4 employees as of Jul 26. Here is PanOptica's employee count trend over the years:

Uncover PanOptica's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PanOptica include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of PanOptica, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
863rd	PanOptica 2009, Bernardsville (United States), Series B	Developer of small molecule therapeutics for ophthalmic disorders	$86M	Novo Holdings, Astellas Venture Management ... & 2 others	40/100